These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37823804)

  • 1. Cure Rare Disease: An Initiative to Enable N of 1 Gene Editing.
    Horgan RW
    Hum Gene Ther; 2023 Oct; 34(19-20):980-981. PubMed ID: 37823804
    [No Abstract]   [Full Text] [Related]  

  • 2. A revealing flaw.
    Leslie M
    Science; 2021 Feb; 371(6530):663-665. PubMed ID: 33574194
    [No Abstract]   [Full Text] [Related]  

  • 3. Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases.
    Papasavva P; Kleanthous M; Lederer CW
    Mol Diagn Ther; 2019 Apr; 23(2):201-222. PubMed ID: 30945166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review.
    Syding LA; Nickl P; Kasparek P; Sedlacek R
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases.
    Wu SS; Li QC; Yin CQ; Xue W; Song CQ
    Theranostics; 2020; 10(10):4374-4382. PubMed ID: 32292501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR-Cas System: The Current and Emerging Translational Landscape.
    Bhokisham N; Laudermilch E; Traeger LL; Bonilla TD; Ruiz-Estevez M; Becker JR
    Cells; 2023 Apr; 12(8):. PubMed ID: 37190012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticles-Mediated CRISPR/Cas Gene Editing Delivery System.
    Saw PE; Cui GH; Xu X
    ChemMedChem; 2022 May; 17(9):e202100777. PubMed ID: 35261159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Editing and Modulation: the Holy Grail for the Genetic Epilepsies?
    Carpenter JC; Lignani G
    Neurotherapeutics; 2021 Jul; 18(3):1515-1523. PubMed ID: 34235638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The CRISPR-Cas system: beyond genome editing].
    Croteau FR; Rousseau GM; Moineau S
    Med Sci (Paris); 2018 Oct; 34(10):813-819. PubMed ID: 30451675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in CRISPR/Cas gene therapy for inborn errors of immunity.
    Liu X; Li G; Liu Y; Zhou F; Huang X; Li K
    Front Immunol; 2023; 14():1111777. PubMed ID: 37051232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR gene editing - what are the possibilities for respiratory medicine?
    Harrison PT
    Expert Rev Respir Med; 2022 Apr; 16(4):371-374. PubMed ID: 35313109
    [No Abstract]   [Full Text] [Related]  

  • 13. Translating CRISPR-Cas Therapeutics: Approaches and Challenges.
    Tay LS; Palmer N; Panwala R; Chew WL; Mali P
    CRISPR J; 2020 Aug; 3(4):253-275. PubMed ID: 32833535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Gene Editing with CRISPR: A Laboratory Medicine Perspective.
    Hahn E; Hiemenz M
    Clin Lab Med; 2020 Jun; 40(2):205-219. PubMed ID: 32439069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene editing in dermatology: Harnessing CRISPR for the treatment of cutaneous disease.
    Baker C; Hayden MS
    F1000Res; 2020; 9():281. PubMed ID: 32528662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Promise and Challenge of In Vivo Delivery for Genome Therapeutics.
    Wilson RC; Gilbert LA
    ACS Chem Biol; 2018 Feb; 13(2):376-382. PubMed ID: 29019396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling Rare Bone Diseases in Animals.
    O'Brien CA; Morello R
    Curr Osteoporos Rep; 2018 Aug; 16(4):458-465. PubMed ID: 29802575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gene editing technology and its recent progress in disease therapy].
    Niu XR; Yin SM; Chen X; Shao TT; Li DL
    Yi Chuan; 2019 Jul; 41(7):582-598. PubMed ID: 31307968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas gene therapy.
    Zhang B
    J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mini review: genome and transcriptome editing using CRISPR-cas systems for haematological malignancy gene therapy.
    Elliott EK; Haupt LM; Griffiths LR
    Transgenic Res; 2021 Apr; 30(2):129-141. PubMed ID: 33609253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.